Tekla Life Sciences Inves... (HQL)
NYSE: HQL
· Real-Time Price · USD
16.50
-0.08 (-0.48%)
At close: Oct 17, 2025, 3:59 PM
16.50
-0.02%
After-hours: Oct 17, 2025, 06:24 PM EDT
Tekla Life Sciences Investors Income Statement
Financials in USD. Fiscal
year is
October - September.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Period Ending | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 |
Revenue | 86.69M | 39.39M | 31.86M | 45.02M |
Cost of Revenue | n/a | 5.24M | 5.55M | 6.08M |
Gross Profit | 86.69M | 18.28M | 26.31M | 38.95M |
Operating Income | 85.3M | -5.24M | -104.6M | 64.53M |
Interest Income | 1.04M | 204.45K | 50.09K | n/a |
Pretax Income | 85.3M | 22.35M | -104.6M | 64.53M |
Net Income | 85.3M | 22.35M | -104.6M | 64.53M |
Selling & General & Admin | 1.33M | 903.14K | 1.08M | 844.02K |
Research & Development | n/a | n/a | -3.28 | n/a |
Other Expenses | 56.66K | 268.31K | 275.97K | 313.69K |
Operating Expenses | 1.39M | 1.17M | 1.35M | 1.16M |
Interest Expense | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.39M | 17.03M | 136.47M | -19.51M |
Income Tax Expense | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 28.06M | 28.29M | 25.68M | 24.26M |
Shares Outstanding (Diluted) | 28.06M | 28.29M | 25.68M | 24.26M |
EPS (Basic) | 3.04 | 0.79 | -4.07 | 2.66 |
EPS (Diluted) | 3.04 | 0.79 | -4.07 | 2.66 |
EBITDA | 85.3M | 22.35M | -104.61M | 64.54M |
EBIT | 85.3M | 22.35M | -104.61M | 64.54M |
Depreciation & Amortization | 1.92M | 27.6M | 2.99M | 4.14M |
Source: Financial Modeling Prep. Financial Sources.